Benjamin Halladay

Chief Financial Officer

CFO Analyst — Intern, Finance Department

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year	Company	Role	Salary	Bonus	Stock awards	Option awards	Incentive	Other	Total
2025	Esperion Therapeutics, Inc. (ESPR)	Chief Financial Officer	$495,833	—	$357,000	$239,852	$247,500	$11,750	$1,351,935
2024	Esperion Therapeutics, Inc. (ESPR)	Chief Financial Officer	$467,333	—	$348,500	$305,969	$235,125	$11,500	$1,368,427

Executive changes

Appointed Chief Financial Officer at Esperion Therapeutics, Inc. (ESPR)
2022-11-16

Earnings-call appearances

Esperion Therapeutics, Inc. Q4 FY2025 Earnings Call
Esperion Therapeutics, Inc. (ESPR)

2026-03-10
Esperion Therapeutics, Inc. Q3 FY2025 Earnings Call
Esperion Therapeutics, Inc. (ESPR)

2025-11-06
Esperion Therapeutics, Inc. Q2 FY2025 Earnings Call
Esperion Therapeutics, Inc. (ESPR)

2025-08-05
Esperion Therapeutics, Inc. Q4 FY2024 Earnings Call
Esperion Therapeutics, Inc. (ESPR)

2025-01-16
Esperion Therapeutics, Inc. Q1 FY2024 Earnings Call
Esperion Therapeutics, Inc. (ESPR)

2024-05-07
Esperion Therapeutics, Inc. Q4 FY2023 Earnings Call
Esperion Therapeutics, Inc. (ESPR)

2024-02-27
Esperion Therapeutics, Inc. Q2 FY2023 Earnings Call
Esperion Therapeutics, Inc. (ESPR)

2023-08-01
Esperion Therapeutics, Inc. Q1 FY2023 Earnings Call
Esperion Therapeutics, Inc. (ESPR)

2023-05-09
Esperion Therapeutics, Inc. Q4 FY2022 Earnings Call
Esperion Therapeutics, Inc. (ESPR)

2023-01-09
Esperion Therapeutics, Inc. Q3 FY2022 Earnings Call
Esperion Therapeutics, Inc. (ESPR)

2022-11-01